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j our na l ho me page: www.elsev ier .com/ locate /vacc ineorewordStrong national immunization programs in the Americas have
aved the way for the elimination of vaccine preventable diseases,
hile simultaneously strengthening the capacity and infrastruc-
ure of national health systems. Globally, vaccines together with
ther public health interventions have also greatly reduced child-
ood mortality. In an effort to sustain these advances, the
orld Health Assembly approved the Global Vaccine Action Plan
2010–2020), which aims to ensure the delivery of vaccines to all
eoples. While this aspirational goal may  be more easily achiev-
ble in the Americas, other Regions continue to struggle to improve
accination coverage and overall health systems strengthening
n support of immunization services. It is evident that robust,
ransparent decision-making structures and processes are essen-
ial to aid policymakers in reaching the best possible decisions with
espect to new vaccine adoption and other associated technical
ssues.
Over the last ten years, the Pan American Health Organiza-
ion’s ProVac Initiative has worked with countries to promote the
evelopment and use of evidence as the basis for decision-making
egarding new vaccine introduction. In weighing introduction
ecisions, the ProVac Initiative has collaborated with national mul-
idisciplinary teams from Ministries of Health to develop needed
nformation on the cost-effectiveness and cost-beneﬁt that new
accines could offer. More recently, ProVac has supported countries
ttp://dx.doi.org/10.1016/j.vaccine.2015.02.001
264-410X/© 2015 Published by Elsevier Ltd.to acquire a better understanding of the investment requirements
as well as the running costs to support sustainable vaccine intro-
duction, over the short, medium and long-term.
To celebrate ProVac’s ten-year anniversary, this supplement
features country-led research to support real-time policymak-
ing, including, inter alia, cost-effectiveness, program costing, and
analyses of ﬁnancial ﬂows. It highlights the work undertaken by
partner organizations collaborating in the ProVac International
Working Group, as well as the Bill and Melinda Gates Foundation-
led Expanded Program on Immunization Costing and Financing
(EPIC) project. Leading researchers and policymakers have con-
tributed perspectives on the challenges and opportunities in this
area.
We are very pleased to publish this second supplement with
Vaccine on useful data for policymakers and program managers in
the immunization community.
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